| Previous Close | 62.50 |
| Open | 62.36 |
| Bid | 61.90 x 200 |
| Ask | 62.11 x 1400 |
| Day's Range | 61.75 - 62.28 |
| 52 Week Range | 46.31 - 63.33 |
| Volume | 9,834 |
| Avg. Volume | 12,400 |
| Net Assets | 147.49M |
| NAV | 61.45 |
| PE Ratio (TTM) | N/A |
| Yield | 0.08% |
| YTD Return | 23.34% |
| Beta (3y) | 0.82 |
| Expense Ratio (net) | 0.35% |
| Inception Date | 2011-01-26 |
- Barrons.com•19 days ago
Who Will Win A $6 Billion Lung Caner Biopsy Opportunity?
Among cancers, lung cancer is the deadliest worldwide, largely because of late diagnoses. Morgan Stanley’s David Lewis and his team write that new tools can disrupt the $6 billion lung biopsy market with better precision and diagnostic accuracy—and that a new system developed via a joint venture between Intuitive Surgical (ISRG) and Fosun International (656.Hong Kong), might be just that tool. Lewis writes that currently, lung biopsy methods have low yields and carry risks, which delays diagnosis and treatment, but that the FC system—a robotic controlled biopsy system using 3D imaging technology to target potential tumors—is more accurate and comes with fewer side effects, which could lower lung cancer mortality.
- Yahoo Finance•25 days ago
Why $475,000 isn't actually that expensive for Novartis's new drug
The price tag on Novartis' new cancer drug may be a bargain
- Yahoo Finance•26 days ago
Trump can lower U.S. drug prices by fixing NAFTA
Without intellectual property, there is no innovation—and as we’re rapidly discovering, no customers.
